WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124758
CAS#: 105920-77-2
Description: Camonagrel is a novel selective thromboxane synthetase inhibitor.
Hodoodo Cat#: H124758
Name: Camonagrel
CAS#: 105920-77-2
Chemical Formula: C15H16N2O3
Exact Mass: 272.12
Molecular Weight: 272.300
Elemental Analysis: C, 66.16; H, 5.92; N, 10.29; O, 17.63
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Camonagrel; 105920-77-2; Camonagrelum
IUPAC/Chemical Name: 5-(2-imidazol-1-ylethoxy)-2,3-dihydro-1H-indene-1-carboxylic acid
InChi Key: IRWWXLHSNMVHNY-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H16N2O3/c18-15(19)14-3-1-11-9-12(2-4-13(11)14)20-8-7-17-6-5-16-10-17/h2,4-6,9-10,14H,1,3,7-8H2,(H,18,19)
SMILES Code: O=C(C1CCC2=C1C=CC(OCCN3C=CN=C3)=C2)O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 272.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Albet C, Pérez A, Rozman E, Sacristan A, Ortiz JA. Pharmacokinetics of
Camonagrel in experimental animal: rat, rabbit and dog. Eur J Drug Metab
Pharmacokinet. 1998 Apr-Jun;23(2):251-4. doi: 10.1007/BF03189347. PMID: 9725489.
2: Gryglewski RJ, Szczeklik A, Korbut R, Swies J, Musiał J, Krzanowski M, Maga
P. The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of
camonagrel--a new thromboxane synthase inhibitor. Wien Klin Wochenschr.
1995;107(9):283-9. PMID: 7778318.
3: De La Cruz JP, Moreno A, Ruiz-Ruiz MI, García Campos J, Sánchez de la Cuesta
F. Effect of camonagrel, a selective thromboxane synthase inhibitor, on retinal
vascularization in experimental diabetes. Eur J Pharmacol. 1998 May
29;350(1):81-5. doi: 10.1016/s0014-2999(98)00233-7. PMID: 9683018.
4: Villalobos MA, De La Cruz JP, Escalante R, Arrebola MM, Guerrero A, Sánchez
de la Cuesta F. Effects of camonagrel, a selective inhibitor of platelet
thromboxane synthase, on the platelet-subendothelium interaction. Pharmacology.
2003 Sep;69(1):44-50. doi: 10.1159/000071266. PMID: 12886030.
5: Partyka L, Dembińska-Kieć A, Pankiewicz J, Dudek D, Hartwich J, Siedlecki A,
Pawlus E, Marquez-Perez M, Torres-Herrera J. An inhibitory effect of
camonagrel-a new thromboxane synthase inhibitor, on P-selectin-mediated
platelet/PMN adhesion. Platelets. 1996;7(3):169-72. doi:
10.3109/09537109609023576. PMID: 21043596.
